ClinicalTrials.gg
RecruitingNCT00500123ACTUpdated Nov 24, 2025

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

An observational study in Alpha-1 Antitrypsin Deficiency, sponsored by University of Florida. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by University of Florida · Observational

How we know

From the registry’s dates

  • Started Jan 2001; still recruiting 25 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Planned enrollment
Largest of 26
50,000 · median 190
Started
2001
with 1 other
Observational
26 of 81
8 open now
Primary completion
2050-01
later than 20 of 20 live
Registered
15th of 81
by date
Lead sponsor
6 of 81
University of Florida

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one has the largest planned enrollment of the 26 observational ones that give a count, is one of 2 that started in 2001, is one of 26 observational ones, reaches primary completion later than 20 of the 20 other live ones, and was the 15th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.

Read the detailed description

Genetic testing for alpha-1 antitrypsin deficiency is sometimes delayed despite established testing indications. All genetic tests have risks and possible benefits. The ACT study evaluates the population demographics, reasons for testing, and outcomes through a confidential testing program. Co-morbidities of alpha-1 antitrypsin deficiency other than lung and liver disease are being investigated. Concerns about genetic confidentiality are lessened in this study by a coded testing procedure that returns results through the mail to study participants.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency

Keywords

  • alpha-1
  • antitrypsin
  • AAT
  • genetic testing
  • alpha-1 antitrypsin deficiency
  • AATD
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Individuals choosing to test at home for alpha-1 antitrypsin deficiency.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis of symptoms or family genetic risk.

Exclusion criteria

Exclusion Criteria:

  • Any person who has already had genotype and AAT level testing completed and has a qualified result.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50,000 participants (estimated)
Target follow-up
50 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • ProcedureAlpha-1 Antitrypsin Genotype

    Home fingerstick testing for alpha-1 antitrypsin genotype

06

What researchers measure

Primary outcomes

  1. Structured questionnaire responses on the risks and benefits of testing.

    Rotating questionnaires assess the clinical course and co-morbidities associated with different genotypes of alpha-1 antitrypsin deficiency.

    Time frame: Before and after alpha-1 antitrypsin testing

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Coors ME, Moseley R, McGorray S. Informed consent process in Alpha-1 testing of at-risk children: views of parents and adults tested as children. COPD. 2011 Feb;8(1):30-8. doi: 10.3109/15412555.2010.541958. PubMed 21299476 ↗
  • Holm KE, Borson S, Sandhaus RA, Ford DW, Strange C, Bowler RP, Make BJ, Wamboldt FS. Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD. 2013 Apr;10(2):226-34. doi: 10.3109/15412555.2012.719049. PubMed 23547634 ↗
  • Stoller JK, Strange C, Schwarz L, Kallstrom TJ, Chatburn RL. Detection of alpha-1 antitrypsin deficiency by respiratory therapists: experience with an educational program. Respir Care. 2014 May;59(5):667-72. doi: 10.4187/respcare.02817. Epub 2013 Oct 8. PubMed 24106322 ↗
  • Strange C, Dickson R, Carter C, Carpenter MJ, Holladay B, Lundquist R, Brantly ML. Genetic testing for alpha1-antitrypsin deficiency. Genet Med. 2004 Jul-Aug;6(4):204-10. doi: 10.1097/01.gim.0000132669.09819.79. PubMed 15266208 ↗
  • Strange C, Moseley MA, Jones Y, Schwarz L, Xie L, Brantly ML. Genetic testing of minors for alpha1-antitrypsin deficiency. Arch Pediatr Adolesc Med. 2006 May;160(5):531-4. doi: 10.1001/archpedi.160.5.531. PubMed 16651497 ↗
  • Carpenter MJ, Strange C, Jones Y, Dickson MR, Carter C, Moseley MA, Gilbert GE. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med. 2007 Feb;33(1):22-8. doi: 10.1207/s15324796abm3301_3. PubMed 17291167 ↗
  • McGee D, Strange C, McClure R, Schwarz L, Erven M. The Alpha-1 Association Genetic Counseling Program: an innovative approach to service. J Genet Couns. 2011 Aug;20(4):330-6. doi: 10.1007/s10897-011-9355-z. Epub 2011 Mar 19. PubMed 21424325 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2001 (actual). Primary completion is estimated for Jan 2050, 588 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2007
First posted
Jul 12, 2007
StartActual
Jan 2001
Primary completionEst.
Jan 2050
CompletionEst.
Jan 2050
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00500123
Responsible party
Sponsor
First posted
Jul 12, 2007
Start date
Jan 2001
Primary completion
Jan 2050 (estimated)
Completion
Jan 2050 (estimated)
Last update
Nov 24, 2025

Study contacts

Michelle Owens, RN, BSN
Contact
Sandra.Owens@medicine.ufl.edu
352-273-6339
Allison Faunce, B.A.
Contact
Allison.Faunce@medicine.ufl.edu
352-273-8666
Karina Serban, M.D.
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion